Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference
JUSTIN TALLIS/AFP via Getty Images

By John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle

Nov. 8, 2024

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
, , ,
Submit a correction requestReprints

  1. John Wilkerson

    Washington Correspondent

    John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care.

  2. Lizzy Lawrence

    FDA Reporter

    Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter.

  3. Rachel Cohrs Zhang

    Chief Washington Correspondent

    Rachel Cohrs Zhang reports on the intersection of health policy and business in Washington. She covers Capitol Hill, lobbying, and federal agencies. Her primary areas of focus are the pharmaceutical and hospital industries. She is also the co-author of the free, twice-weekly D.C. Diagnosis newsletter.

  4. Sarah Owermohle

    Washington Correspondent

    Sarah Owermohle reports on the administration’s health care initiatives, federal health policy, and its intersection with politics and the courts. She joined STAT in 2022 after covering health policy at Politico. She is also the co-author of the free, twice-weekly D.C. Diagnosis newsletter.